Gil Roth12.19.13
NewLink Genetics has launched a first-in-human Phase I trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. HyperAcute Renal Immunotherapy is comprised of two allogeneic renal cell cancer cell lines engineered to express the murine alpha(1,3)GT gene.
The dose-escalation study is designed primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in as many as 20 patients with recurrent or refractory, metastatic clear-cell renal cancer.
The dose-escalation study is designed primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in as many as 20 patients with recurrent or refractory, metastatic clear-cell renal cancer.